Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom. Show more
Location: Mailpoint 810, South Block, Southampton, SO16 6YD, United Kingdom | Website: https://www.synairgen.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
9.097M
52 Wk Range
$0.00 - $0.07
Previous Close
$0.00
Open
$0.00
Volume
400
Day Range
$0.00 - $0.00
Enterprise Value
-8.531M
Cash
8.591M
Avg Qtr Burn
-11.96M
Insider Ownership
0.57%
Institutional Own.
87.22%
Qtr Updated
06/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SG016 / SNG001 Details COVID-19 | Phase 2/3 Update | |
SNG001 (IFN-β) Details Skin disease/disorder, Psoriasis | Phase 2 Update |